Table 1:

Select baseline characteristics

CharacteristicUnweightedWeighted*
Donepezil, no. (%)
n = 152 300
Rivastigmine or galantamine, no. (%)
n = 68 053
Standardized difference, %Donepezil, no. (%)
n = 152 300
Rivastigmine or galantamine, no. (%)
n = 152 161
Standardized difference, %
Demographics
Age, yr, mean ± SD81.2 ± 6.680.9 ± 6.6581.2 ± 6.681.2 ± 10.00
Women94 254 (61.9)40 956 (60.2)394 254 (61.9)94 122 (61.9)0
Year of cohort entry
 2002–200425 908 (17.0)13 863 (20.4)925 908 (17.0)25 502 (16.8)1
 2005–200727 767 (18.2)17 274 (25.5)1827 767 (18.2)27 756 (18.2)0
 2008–201030 605 (20.1)18 487 (27.2)1730 605 (20.1)30 830 (20.3)0
 2011–201334 771 (22.8)10 245 (15.0)2034 771 (22.8)34 998 (23.0)0
 2014–201733 249 (21.9)8184 (12.0)2733 249 (21.9)22 547 (14.8)0
Long-term care15 415 (10.1)9813 (14.4)1315 415 (10.1)18 266 (12.0)6
Rural20 046 (13.2)7489 (11.0)720 046 (13.2)20 535 (13.5)1
Income quintile
 1 (lowest)30 579 (20.1)14 245 (20.9)230 579 (20.1)30 669 (20.2)0
 231 615 (20.8)14 313 (21.0)031 615 (20.8)31 637 (20.8)0
 329 899 (19.6)13 257 (19.5)029 899 (19.6)30 257 (19.9)1
 430 038 (19.7)13 104 (19.3)130 038 (19.7)30 110 (19.8)0
 5 (highest)29 641 (19.5)12 891 (18.9)229 641 (19.5)29 488 (19.4)0
Comorbidity
Atrial fibrillation12 961 (8.5)6113 (9.0)212 961 (8.5)12 953 (8.5)0
Coronary artery disease43 339 (28.5)21 600 (31.7)743 339 (28.5)43 265 (28.4)0
Chronic liver disease4071 (2.7)1928 (2.8)14071 (2.7)4020 (2.6)0
Chronic lung disease36 418 (23.9)17 082 (25.1)336 418 (23.9)36 307 (23.9)0
Chronic kidney disease12 089 (7.9)5505 (8.1)112 089 (7.9)12 188 (8.0)0
Depression21 834 (14.3)11 121 (16.3)621 834 (14.3)21 905 (14.4)0
Diabetes mellitus25 056 (16.5)11 570 (17.0)125 056 (16.5)25 094 (16.5)0
Heart failure22 811 (15.0)11 349 (16.7)522 811 (15.0)22 863 (15.0)0
Parkinson disease7710 (5.1)5660 (8.3)137710 (5.1)8022 (5.3)1
Peripheral vascular disease2495 (1.6)1228 (1.8)22495 (1.6)2487 (1.6)0
Seizure disorder1505 (1.0)787 (1.2)21505 (1.0)1492 (1.0)0
Sepsis1889 (1.2)894 (1.3)11889 (1.2)1929 (1.3)0
Stroke7629 (5.0)4315 (6.3)67629 (5.0)7688 (5.1)0
Prescribing physician characteristic
Specialty
 Cardiology351 (0.2)87 (0.1)3351 (0.2)170 (0.1)2
 General practice97 325 (63.9)40 176 (59.0)1097 325 (63.9)91 886 (60.4)7
 Geriatric medicine18 764 (12.3)10 371 (15.2)818 764 (12.3)23 848 (15.7)10
 Nephrology86 (0.1)47 (0.1)086 (0.1)107 (0.1)1
 Neurology8565 (5.6)4312 (6.3)38565 (5.6)8879 (5.8)1
 Other10 387 (6.8)5394 (7.9)110 387 (6.8)11 469 (7.5)3
Rural practice14 456 (9.5)4970 (7.3)814 456 (9.5)12 943 (8.5)3
ACE inhibitors43 752 (28.7)21 012 (30.9)543 752 (28.7)43 906 (28.9)0
Angiotensin receptor blockers18 042 (11.8)7 975 (11.7)018 042 (11.8)17 918 (11.8)0
Antidepressants40 251 (26.4)20 102 (29.5)740 251 (26.4)40 630 (26.7)1
Antiepileptics6417 (4.2)2902 (4.3)06417 (4.2)6430 (4.2)0
Antipsychotics15 559 (10.2)9798 (14.4)1315 559 (10.2)15 807 (10.4)0
β-blockers39 857 (26.2)18 794 (27.6)339 857 (26.2)39 717 (26.1)0
Calcium channel blockers38 049 (25.0)17 485 (25.7)238 049 (25.0)37 863 (24.9)0
Colchicine45 (0.0)16 (0.0)145 (0.0)39 (0.0)0
Fibrates1912 (1.3)958 (1.4)11912 (1.3)1918 (1.3)0
Diuretics39 977 (26.2)18 700 (27.5)339 977 (26.2)39 962 (26.3)0
Histamine-2 receptor antagonist8610 (5.7)4530 (6.7)48610 (5.7)8562 (5.6)0
Statins60 433 (39.7)27 197 (40.0)160 433 (39.7)60 366 (39.7)0
  • Note: ACE = angiotensin-converting enzyme, SD = standard deviation.

  • * Individuals were weighted using inverse probability of treatment weights, based on propensity scores, to create a weighted cohort in which exposure groups were balanced across all measured baseline characteristics.

  • Unless stated otherwise.

  • Standardized difference assesses between-group means as a percentage of the pooled standard deviation, with a difference less than 10% considered negligible.